DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for alpha 1-antitrypsin deficiency — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAlpha 1-antitrypsin deficiency maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for alpha 1-antitrypsin deficiency is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
serpin family A member 1 (SERPINA1) — SERPINA1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 5rdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 1IZ2 · 2.2 Å · ligand (5R)-5-[(2R)-2-hydroxynonyl]-beta-D-xylulofuranose (Z6W). Experimental structure, not a prediction.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Zenodo (CERN European Organization for Nuclear Research) · 2025 · 0 citations · open access
Alpha-1 Antitrypsin Deficiency: Current landscape of detection, management, and treatment
AbstractNarrative review summarising current approaches to detection, clinical management, and emerging treatment strategies for Alpha-1 Antitrypsin Deficiency (AATD). Provides an overview of disease mechanisms, diagnostic pathways, therapeutic options, and future directions in AATD care.
Family Medicine & Primary Care Review · 2015 · 0 citations · open access
Alpha1-antitrypsin deficiency – misconceptions about an important clinical problem
AbstractA -przygotowanie projektu badania, B -zbieranie danych, C -analiza statystyczna, D -interpretacja danych, E -przygotowanie maszynopisu, F -opracowanie pimiennictwa, G -pozyskanie funduszy wrodzony niedobr alfa-1 antytrypsyny (ang. alpha-1 antitrypsin deficiency, aatD) jest jednym z najczstszych zaburze genetycznych, rozpoznawanym rzadko pomimo szerokiego spektrum manifestacji klinicznej (przewleka obturacyjna choroba puc, rozstrzenie oskrzeli, astma oskrzelowa, marsko wtroby, rak wtrobowokomrkowy, zapalenie tkanki podskrnej
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
